Lexicon Pharmaceuticals, Inc (LXRX)

Etorro trading 970x250
Lexicon Pharmaceuticals, Inc (LXRX) Logo

About Lexicon Pharmaceuticals, Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Address: 8800 Technology Forest Place, The Woodlands, TX, United States, 77381-1160

Lexicon Pharmaceuticals, Inc News and around…

Latest news about Lexicon Pharmaceuticals, Inc (LXRX) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
12 Aug, 2022 FinancialContent

Upgrades Mizuho upgraded the previous rating for Safehold Inc (NYSE:SAFE) from Neutral to Buy. For the second quarter, ...

Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
05 Aug, 2022 Yahoo! Finance

THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001 (the “Common Stock”), pursuant to the full exercise of the underwriters’ option to purchase additional shares in connection with Lexicon’s previously announced public offering of Common Stock. After giving effect to the full exercise of the underwriters’ option to purchase add

Recap: Lexicon Pharmaceuticals Q2 Earnings
02 Aug, 2022 FinancialContent

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what ...

Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
02 Aug, 2022 Yahoo! Finance

Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA,with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neuropathic Pain Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2022 and pro

Top Buys by Directors: Debbane's $2.5M Bet on LXRX
02 Aug, 2022 FinancialContent

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Tuesday 8/2 Insider Buying Report: LXRX, BX
02 Aug, 2022 FinancialContent

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

More Than $40 Million Bet On This Penny Stock? Check Out These 3 Penny Stocks Insiders Are Buying
02 Aug, 2022 FinancialContent

U.S. gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders ...

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
02 Aug, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Allarity To Shift Focus On ...

This Financial Services Is Trading Higher By Over 217%; Here Are 38 Stocks Moving Premarket
02 Aug, 2022 FinancialContent

Gainers AMTD IDEA Group (NYSE: AMTD) rose 217.3% to $6.60 in pre-market trading after jumping 18% on Monday. The company owns 90%+ ...

Earnings Scheduled For August 2, 2022
02 Aug, 2022 FinancialContent

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share ...

Lexicon Pharmaceuticals Earnings Preview
01 Aug, 2022 FinancialContent

Lexicon Pharmaceuticals (NASDAQ:LXRX) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors ...

Investors Grab LXRX 6.0% Cheaper Than Its Secondary Stock Offering
01 Aug, 2022 FinancialContent

Looking back to 4 days ago, Lexicon Pharmaceuticals, Inc. (LXRX) priced a 16,843,600 share secondary stock offering at $2.50 per share..

Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
29 Jul, 2022 Yahoo! Finance

THE WOODLANDS, Texas, July 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT that day to discuss its financial and operating results and to provide a general business update. Dial-in InformationDial-in Number: (888) 886-7786Conference ID: 78319165 Replay InformationDial-in Numb

Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket
29 Jul, 2022 FinancialContent

Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading. ThermoGenesis Holdings, Inc. ...

This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
29 Jul, 2022 FinancialContent

Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is ...

12 Health Care Stocks Moving In Thursday's Intraday Session
28 Jul, 2022 FinancialContent

Gainers Athersys (NASDAQ:ATHX) stock rose 73.2% to $0.33 during Thursday's regular session. The current volume of ...

Why Shares of Solar Companies Are Trading Higher? 64 Stocks Moving In Thursday's Mid-Day Session
28 Jul, 2022 FinancialContent

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 231% to $2.63 on news that the company will be acquired By Henry Crown ...

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
28 Jul, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approves GSK's ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
28 Jul, 2022 FinancialContent

Gainers Better Therapeutics (NASDAQ:BTTX) shares moved upwards by 67.3% to $2.56 during Thursday's pre-market ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
28 Jul, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It's time for another dive into the biggest pre-market stock movers as we check out what's happening Thursday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” Cash Holders Could Get Hit Hard THIS FRIDAY

Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
28 Jul, 2022 Yahoo! Finance

THE WOODLANDS, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the “Common Stock”). The shares of Common Stock are being offered at a public offering price of $2.50 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be approximately $42.

Why Meta Platforms Is Trading Lower By More Than 6%: Here Are 34 Stocks Moving Premarket
28 Jul, 2022 FinancialContent

Gainers JAKKS Pacific, Inc. (NASDAQ: JAKK) rose 34.7% to $23.01 in pre-market trading after the company reported ...

Recap of Wednesday's Biotech Catalysts - End of The Day Summary
27 Jul, 2022 FinancialContent

IDEAYA Biosciences (NASDAQ: IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Jul, 2022 FinancialContent

Gainers Ensysce Biosciences (NASDAQ:ENSC) shares increased by 6.6% to $0.59 during Wednesday's after-market session. This ...

Lexicon Announces Proposed Public Offering Of Common Stock
27 Jul, 2022 Yahoo! Finance

THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the “Common Stock”). In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of Common Stock. There can be no assurance as to whether or when the offering may be compl

FDA Accepts Lexicon's New Drug Application For Review In Heart Failure Setting
27 Jul, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has accepted for review Lexicon Pharmaceuticals ‘ (NASDAQ: LXRX) New Drug Application ...

Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
27 Jul, 2022 Yahoo! Finance

NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 PeopleTHE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of heart failure. The FDA assigned a standard review for the NDA filin

Add Up The Pieces: VHT Could Be Worth $287
06 Jul, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $287.16 per unit.

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
06 Jul, 2022 FinancialContent

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday. Rubicon Technology, Inc. ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
05 Jul, 2022 FinancialContent

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 52.4% to $0.92 during Tuesday's regular session. Nuwellis's ...

Lexicon Pharmaceuticals, Inc (LXRX) is a NASDAQ Common Stock listed in , ,

970x250